Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy

Medical Oncology

Volumn 13, Issue 2, 1996, Pages 111-117

  Einzig, Avi I ^a,c   Schuchter, Lynn M ^b   Recio, Adri ^b   Coatsworth, Susan ^a   Rodriquez, Roberto ^b   Wiernik, Peter H ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Docetaxel; Malignant melanoma

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; VOMITING;

EID: 0030468023     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02993861     Document Type: Article

References (38)

1. Karjalainen, S. and Hakulinen, T. (1988) Survival and prognostic factors of patients with skin melanoma. Cancer 62, 2274.
2. Marsoni, S., Hoth, D. and Simon, R. (1987) Clinical drug development: An analysis of phase II trials, 1970-1985. Cancer Treat. Rep. 71, 71.
3. Bissery, M.C., Bayssas, M., Lavelle, F. et al. (1990) Preclinical evaluation of intravenous Taxotere (RP 56976, WSC 628503) a Taxol analog. Proc. Am. Assoc. Cancer Res. (abstr.) 31, 417.
4. Extra, J.M., Rousseau, F., Bruno, R. et al. (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. 53, 1037-42.
5. Bisset, D., Setanoians, A., Cassidy, J. et al. (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res. 53, 523-7.
6. Pazdur, R., Newmann, R.A., Newmann, B.M. et al. (1992) Phase I trial of Taxotere, five day schedule. J. Natl. Cancer Inst. 84, 1781-8.
7. Burns, H.A., Irvin, R., Kuhn, J. et al. (1993) Phase I trial of Taxotere administered as either a 24-hour or 6-hour infusion. J. Clin. Oncol. 11, 950-8.
8. Tomiak, E., Piccart, M.J., Kerger, J. et al. (1994) Phase I study of docetaxel administered as an intravenous 1-hour infusion on a weekly basis. J. Clin. Oncol. 12, 1458-67.
9. Francis, P.A., Rigas, J.R., Kris, M.G. et al. (1994) Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J. Clin. Oncol. 12, 1232-7.
10. Fossella, F.V., Lee, J.S., Murphy, W.K. et al. (1994) Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J. Clin. Oncol. 12, 1238-44.
11. Fossella, F.V., Lee, J.S., Shinn, D.M. et al. (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J. Clin. Oncol. 13, 645-51.
12. Cerny, T., Kaplan, S., Pavlidis, N. et al. (1994) Docetaxel (Taxotere) is active in non-small cell lung cancer: A phase II study of the EORTC early clinical trials group (ECTG). Br. J. Cancer 70, 384-7.
13. Fossella, F.V., Lee, J.S., Berille, J. et al. (1995) Summary of the phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of non-small cell lung cancer. Semin. Oncol. (suppl 4) 22, 22-29.
14. Ten Bokkel Huinink, W., Prove, A.M., Piccart, M. et al. (1994) A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann. Oncol. 5, 527-32.
15. Chevalier, B., Fumoleau, P., Kerbrat, P. et al. (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for the Research and Treatment of Cancer. J. Clin. Oncol. 13, 314-22.
16. Dieras, V., Fumoleau, P., Chevalier, B. et al. (1994) Second EORTC Clinical Screening Group (CSG) phase II trial of taxotere (docetaxel) as first line chemotherapy in advanced breast cancer. Proc. Am. Soc. Clin. Oncol. (abstr.) 13, 78.
17. Trudeau, M.E., Eisenhauer, E., Lofters, W. et al. (1993) Phase II study of Taxotere as first-line chemotherapy for metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study. Proc. Am. Soc. Clin. Oncol. (abstr.) 12, 64.
18. Seidman, A.D., Hudis, C., Crown, J.P. et al. (1993) Phase II evaluation of Taxotere (RP 56976, NSC 628503) as initial chemotherapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (abstr.) 12, 63.
19. Ravdin, P.M. and Valero, V. (1995) Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer. Semin. Oncol. (suppl 4) 22, 17-21.
20. Francis, P., Schneider, J., Hann, L. et al. (1994) Phase II trial of docetaxel in patients with platinum refractory ovarian cancer. J. Clin. Oncol. 12, 2301-8.
21. Piccart, M.J., Gore, M., ten Bokkel Huinnink, W. et al. (1995) Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. J. Natl. Cancer Inst. 87, 676-81.
22. Catimel, G., Vermeij, J., Mattijsen, V. et al. (1994) Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann. Oncol. 5, 533-7.
23. McCaffrey, J., Hilton, S., Bajorin, D. et al. (1995) Docetaxel in patients with advanced transitional cell cancer (TCC) who failed cisplatin-based chemotherapy: A phase II trial. Proc. Am. Soc. Clin. Oncol. (abstr.) 14, 233.
24. Sulkes, A., Smyth, J., Sessa, C. et al. (1994) Docetaxel (Taxotere) in advanced gastric cancer: Result of phase II clinical trial. Br. J. Cancer 70, 380-3.
25. Oken, M.M., Creech, R.H., Tormey, D.C. et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649-55.
26. Bedikian, A.Y., Weiss, G.R., Legha, S.S. et al. (1995) Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J. Clin. Oncol. 13, 2895-9.
27. Aamdal, S., Wolff, I., Kaplan, S. et al. (1994) Docetaxel (Taxotere) in advanced malignant melanoma: A phase II study of the EORTC Early Clinical Trials Group. Eur. J. Cancer 30A, 1064-7.
28. Comis, R.L. (1976) DTIC In malignant melanoma: A perspective. Cancer Treat. Rep. 64, 1123.
29. Luce, J.K. (1972) Chemotherapy of malignant melanoma. Cancer 30, 1604.
30. Costonza, M.E., Nathanson, L., Schoenfeld, D. et al. (1977) Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 40, 1010.
31. Hill, G.J. II, Krementz, E.T. and Hill, H.Z. (1984) Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma: Late results after complete response to chemotherapy. Cancer 53, 1299.
32. Kirkwood, J.M. and Ernstoff, M. (1986) Potential application of the interferons in oncology: Lessons drawn from studies of human melanoma. Semin. Oncol. 13, 48.
33. Creagan, E.T., Ahman, D.L., Frytak, S. et al. (1986) Recombinant A interferon (IFN-alpha 2A) in the treatment of disseminated malignant melanoma: Analysis of complete and long-term responding patients. Cancer 58, 2576.
34. Rosenberg, S.A., Lotee, M.T., Muul, L.M. et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med. 316, 889.
35. Dutcher, J.P., Gaynor, E., Boldt, D.H. et al. (1991) A phase II study of high-dose continuous infusion interleukin-2 with lymphokine activated killer cells in patients with metastatic melanoma. J. Clin. Oncol. 9, 641.
36. Dutcher, J.P., Creekmore, S., Weiss, G.R. et al. (1989) A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic melanoma. J. Clin. Oncol. 7, 477.
37. Einzig, A.I., Hochster, H., Wiernik, P.H. et al. (1991) A phase II study of Taxol in patients with malignant melanoma. Invest. New Drugs 9, 59-64.
38. Legha, S.S., Ring, S., Papadeopoulos, N. et al. (1990) A phase II study in patients with metastatic melanoma. Cancer 65, 2478-81.